RxDoctor Payments Data

Joe Fahed, MD

Clinical Cardiac Electrophysiology · Houston, TXNPI 1558527770

Payments from drug & device makers

$23,553in general payments, 2019–2025

Across 747 payments — averaging $31.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Medtronic$5K
  • Boston Scientific$4K
  • Biosense Webster, Inc.$3K
  • Biotronik Inc.$2K
  • Impulse Dynamics (USA) Inc.$476
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$7003%
  • Travel & lodging$8,57036%
  • Food & beverage$14,07960%
  • Education$2031%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,553 in reported general payments places this provider in the 35th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$1,011,558
Medicare patients
753
Services billed
6,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban328$375,547
XareltoRivaroxaban98$135,277
MultaqDronedarone Hcl24$40,381
Dofetilide82$16,896
EntrestoSacubitril/Valsartan14$13,949
Droxidopa20$6,295
Metoprolol Succinate332$5,864
Flecainide Acetate122$4,702
Amiodarone Hcl151$4,491
Digoxin73$3,890
SotalolSotalol Hcl100$2,009
Colchicine106$1,781
ClopidogrelClopidogrel Bisulfate85$1,232
Midodrine Hcl18$1,101
Pantoprazole Sodium114$1,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$146$375,547328 claims
Johnson & JohnsonXarelto$51$135,27798 claims
Sanofi-aventis U.S. LLCMultaq$39$40,38124 claims
NovartisEntresto$92$13,94914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →